BOOK
PET-Based Molecular Imaging in Evolving Personalized Management Design, An Issue of PET Clinics, E-Book
(2016)
Additional Information
Book Details
Abstract
This issue of PET Clinics focuses on PET-Based Molecular Imaging in Evolving Personalized Management Design, and is edited by Drs. Abass Alavi and Sandip Basu. Articles will include: PET-Based Personalized Medicine: An Unavoidable Path for the Foreseeable Future; Personalized Management Approaches in Lymphoma: Help from PET; PET-CT in Head-Neck Malignancies: the Implications for Personalized Clinical Practice; PET Imaging of Skeletal Metastases and its Role in Personalising Further Management; PET-Based Molecular Imaging in Designing a Personalized Management Model in Neuroendocrine Tumors; Personalized Clinical Decision Making in GI Malignancies: Where Can PET Help?; PET in Breast Carcinoma: Can it Aid in Developing a Personalized Treatment Design; PET and Thyroid Cancer: Can it Help in Evolving a Personalized Treatment Design?; PET Imaging Towards Individualized Management of Urological and Gynaecological Malignancies; The Possible Role of PET Imaging towards Individualized Management of Bone and Soft Tissue Malignancies; PET-Based Personalized Management of Inflammatory Disorders; PET-Based Radiation Oncology; PET-Based Interventional Radiology; The Current and Evolving Role of PET in Personalized Management of Lung Carcinoma, and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| PET-Based Molecular Imaging in Evolving Personalized Management Design\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface\r | vii | ||
| PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future\r | vii | ||
| Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging\r | vii | ||
| PET/CT in Head-neck Malignancies: The Implications for Personalized Clinical Practice\r | viii | ||
| PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors\r | viii | ||
| The Current and Evolving Role of PET in Personalized Management of Lung Cancer\r | viii | ||
| PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies\x0B | viii | ||
| Personalized Clinical Decision Making in Gastrointestinal Malignancies: The Role of PET\r | ix | ||
| The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies\r | ix | ||
| PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?\r | ix | ||
| PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management\r | ix | ||
| PET-Based Thoracic Radiation Oncology\r | x | ||
| PET-Based Percutaneous Needle Biopsy\r | x | ||
| PET-Based Personalized Management of Infectious and Inflammatory Disorders\r | x | ||
| PET CLINICS\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| October 2016 | xi | ||
| January 2017 | xi | ||
| April 2017 | xi | ||
| RECENT ISSUES | xi | ||
| April 2016 | xi | ||
| January 2016 | xi | ||
| October 2015 | xi | ||
| CME Accreditation Page | xii | ||
| PROGRAM OBJECTIVE | xii | ||
| TARGET AUDIENCE | xii | ||
| LEARNING OBJECTIVES | xii | ||
| ACCREDITATION | xii | ||
| DISCLOSURE OF CONFLICTS OF INTEREST | xii | ||
| UNAPPROVED/OFF-LABEL USE DISCLOSURE | xii | ||
| TO ENROLL | xii | ||
| METHOD OF PARTICIPATION | xiii | ||
| CME INQUIRIES/SPECIAL NEEDS | xiii | ||
| Preface | xv | ||
| REFERENCES | xvi | ||
| PET-Based Personalized Management in Clinical Oncology | 203 | ||
| Key points | 203 | ||
| INTRODUCTION: PERSONALIZED OR PRECISION MEDICINE: ADVANTAGES OF INTEGRATING PET/COMPUTED TOMOGRAPHIC IMAGING IN CLINICAL MA ... | 203 | ||
| TRADITIONAL CLINICAL UTILITIES OF PET/COMPUTED TOMOGRAPHY IN PERSONALIZING DISEASE MANAGEMENT | 204 | ||
| NEWER APPLICATIONS OF PET-BASED DISEASE RESTAGING WITH IMPLICATIONS FOR MANAGEMENT INDIVIDUALIZATION | 204 | ||
| EMERGING APPLICATIONS OF PET/COMPUTED TOMOGRAPHY IN PERSONALIZING DISEASE MANAGEMENT | 205 | ||
| Quantification of Metabolic Activity, Metabolic Tumor Volume, and Total Lesion Glycolysis as Disease Prognosticator | 205 | ||
| PET-Based Risk Adaptive Management in Lymphoma and in Neoadjuvant Treatment Setting | 205 | ||
| Dual Tracer PET Imaging Approach in Individualizing Therapy | 205 | ||
| As a Guide to Multitargets in Molecular-based Therapy | 205 | ||
| Tumor Heterogeneity | 206 | ||
| PET/Computed Tomography–guided Biopsy in Individualized Diagnosis and Appropriate Tumor Grading | 206 | ||
| Detection of Synchronous and Metachronous Primaries and Other Sequelae of Toxic Therapies | 206 | ||
| SUMMARY | 206 | ||
| REFERENCES | 206 | ||
| Personalized Management Approaches in Lymphoma | 209 | ||
| Key points | 209 | ||
| HODGKIN LYMPHOMA | 209 | ||
| DIFFUSE LARGE B-CELL LYMPHOMA | 211 | ||
| OTHER NON-HODGKIN LYMPHOMA SUBTYPES | 213 | ||
| Follicular Lymphoma and Mantle Cell Lymphoma | 213 | ||
| Chronic Lymphocytic Lymphoma | 214 | ||
| CONCLUDING REMARKS RELATED TO THE EVOLVING ROLE OF NOVEL QUANTITATIVE TECHNIQUES IN PERSONALIZED LYMPHOMA MANAGEMENT | 214 | ||
| REFERENCES | 217 | ||
| PET/CT in Head-neck Malignancies | 219 | ||
| Key points | 219 | ||
| INTRODUCTION | 219 | ||
| FLUORODEOXYGLUCOSE F 18 PET/CT | 220 | ||
| PET/CT PROTOCOL | 220 | ||
| QUANTIFICATION OF METABOLIC ACTIVITY AND TUMOR VOLUME | 221 | ||
| MOLECULAR AND GENETIC CHARACTERIZATION OF HEAD AND NECK SQUAMOUS CELL CARCINOMA | 221 | ||
| PET/CT IN HEAD AND NECK SQUAMOUS CELL CARCINOMA AND PERSONALIZED MANAGEMENT | 221 | ||
| UNKNOWN PRIMARY | 221 | ||
| STAGING | 222 | ||
| Primary Tumor | 222 | ||
| Lymph Nodes | 223 | ||
| Sentinel lymphoscintigraphy | 224 | ||
| Distant Metastases | 224 | ||
| RADIATION TREATMENT PLANNING | 224 | ||
| ASSESSMENT OF RESPONSE TO THERAPY | 225 | ||
| SURVEILLANCE | 226 | ||
| PROGNOSIS | 226 | ||
| DETECTION OF SYNCHRONOUS AND METACHRONOUS PRIMARIES | 227 | ||
| DETECTION OF SEQUELAE OF THERAPY | 227 | ||
| Summary | 229 | ||
| The Future of PET-based Individualized Management of Head and Neck Squamous Cell Carcinoma | 229 | ||
| REFERENCES | 230 | ||
| PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors | 233 | ||
| Key points | 233 | ||
| INTRODUCTION: THERAPEUTIC STRATEGIES IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS | 233 | ||
| PERSONALIZED SELECTION OF THE APPROPRIATE THERAPEUTIC STRATEGY: THE TRADITIONAL DETERMINANTS AND THE EVOLVING PLACE OF DUAL ... | 234 | ||
| Case 1: Well-Differentiated (G1) Somatosatin Receptor–Positive and Fluorodeoxyglucose-Negative Pancreatic Neuroendocrine Tumors | 234 | ||
| Outcome | 234 | ||
| Learning point | 234 | ||
| Case 2: Poorly Differentiated (G3) Somatosatin Receptor–Negative and Fluorodeoxyglucose-Positive Neuroendocrine Cancer | 234 | ||
| Case 3: Well-Differentiated (G2) Intermediate Mib1 Index, Somatosatin Receptor–Positive and Fluorodeoxyglucose-Negative Neu ... | 235 | ||
| Outcome | 235 | ||
| The Current and Evolving Role of PET in Personalized Management of Lung Cancer | 243 | ||
| Key points | 243 | ||
| INTRODUCTION | 243 | ||
| MOLECULAR GENETICS IN LUNG CANCER: VALUE OF PET IMAGING | 244 | ||
| Tumor Heterogeneity | 244 | ||
| Epidermal Growth Factor Receptor Mutation in Non–Small Cell Lung Cancer | 245 | ||
| Kras Mutation: Value of PET Imaging | 247 | ||
| Anaplastic lymphoma kinase and ROS-1 mutations | 248 | ||
| PET IMAGING IN ASSESSING RESPONSE TO THERAPY | 248 | ||
| BEYOND 18F-FLUORODEOXYGLUCOSE PET: FUNCTIONAL AND MOLECULAR IMAGING WITH NOVEL PET TRACERS | 249 | ||
| Imaging of Molecular Targets | 249 | ||
| Assessing Cell Proliferation | 251 | ||
| Imaging Hypoxia | 254 | ||
| Imaging Angiogenesis | 255 | ||
| SUMMARY | 255 | ||
| REFERENCES | 256 | ||
| PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies | 261 | ||
| Key points | 261 | ||
| INTRODUCTION | 261 | ||
| PET IN UROLOGIC MALIGNANCIES | 261 | ||
| Renal Cell Carcinoma | 261 | ||
| Targeting angiogenesis in renal cell carcinoma | 262 | ||
| Targeting hypoxia in renal cell carcinoma | 264 | ||
| Targeting carbonic anhydrase IX in renal cell carcinoma | 264 | ||
| Prostate Cancer | 264 | ||
| Targeting the prostate-specific membrane antigen in prostate cancer | 264 | ||
| Targeting the androgen receptor in prostate cancer | 265 | ||
| Urinary Bladder Cancer | 266 | ||
| Targeting angiogenesis in bladder cancer | 266 | ||
| PET IN GYNECOLOGIC MALIGNANCIES | 266 | ||
| Endometrial Cancer | 266 | ||
| Ovarian Cancer | 266 | ||
| Cervical Cancer | 267 | ||
| Targeting estrogen receptor in endometrial and ovarian cancer | 267 | ||
| Targeting folate receptor in endometrial and ovarian cancer | 267 | ||
| Targeting angiogenesis in endometrial, ovarian, and cervical cancer | 268 | ||
| SUMMARY | 269 | ||
| REFERENCES | 269 | ||
| Personalized Clinical Decision Making in Gastrointestinal Malignancies | 273 | ||
| Key points | 273 | ||
| INTRODUCTION | 273 | ||
| GASTRIC CANCER | 274 | ||
| PANCREATIC CANCER | 275 | ||
| COLORECTAL CANCER | 275 | ||
| GASTROINTESTINAL STROMAL TUMORS | 277 | ||
| DISCUSSION | 279 | ||
| REFERENCES | 280 | ||
| The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies | 285 | ||
| Key points | 285 | ||
| INTRODUCTION | 285 | ||
| NORMAL ANATOMY AND IMAGING TECHNIQUE | 286 | ||
| PET/Computed Tomography for Sarcoma Detection and Grading | 287 | ||
| PET/Computed Tomography for Initial Staging and Restaging | 287 | ||
| PET/Computed Tomography and Prediction of Prognosis | 288 | ||
| PET/Computed Tomography and Evaluation of Response to Therapy | 289 | ||
| PET/Computed Tomography in Biopsy | 290 | ||
| IMAGING PROTOCOLS | 290 | ||
| DIFFERENTIAL DIAGNOSIS | 291 | ||
| PITFALLS, PEARLS, VARIANTS | 291 | ||
| DIAGNOSTIC CRITERIA | 292 | ||
| WHAT THE REFERRING PHYSICIAN NEEDS TO KNOW | 293 | ||
| SUMMARY | 293 | ||
| REFERENCES | 293 | ||
| PET/Computed Tomography in Breast Cancer | 297 | ||
| Key points | 297 | ||
| INTRODUCTION | 297 | ||
| PATHOPHYSIOLOGY | 298 | ||
| ROLE OF PET WITH FLUDEOXYGLUCOSE F 18/COMPUTED TOMOGRAPHY | 298 | ||
| RECEPTOR-BASED PET/COMPUTED TOMOGRAPHY | 300 | ||
| 18F-16α-17β-Fluoroestradiol | 300 | ||
| LIMITATIONS | 302 | ||
| SUMMARY | 302 | ||
| REFERENCES | 302 | ||
| PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management | 305 | ||
| Key points | 305 | ||
| INTRODUCTION | 305 | ||
| PATHOPHYSIOLOGY OF SKELETAL METASTASES | 306 | ||
| IMAGING OF SKELETAL METASTASES: AN OVERVIEW | 306 | ||
| PET | 307 | ||
| 18F Sodium Fluoride PET | 307 | ||
| 18F Fluorodeoxyglucose PET/Computed Tomography | 309 | ||
| Choline PET/Computed Tomography | 311 | ||
| Specific PET Tracers | 312 | ||
| PET/MR IMAGING | 313 | ||
| SUMMARY | 314 | ||
| ACKNOWLEDGMENTS | 314 | ||
| REFERENCES | 314 | ||
| PET-Based Thoracic Radiation Oncology | 319 | ||
| Key points | 319 | ||
| INTRODUCTION | 319 | ||
| PET FOR DIAGNOSIS AND STAGING | 320 | ||
| THORACIC RADIATION THERAPY TREATMENT TECHNIQUES | 321 | ||
| PET/COMPUTED TOMOGRAPHY FOR RADIATION THERAPY TARGET DELINEATION | 322 | ||
| PRETREATMENT PET FOR PROGNOSIS AND TO PREDICT TREATMENT RESPONSE | 324 | ||
| POSTTREATMENT PET FOR PROGNOSIS AND TO PREDICT TREATMENT RESPONSE | 325 | ||
| ASSESSMENT OF RADIATION-INDUCED TOXICITY | 326 | ||
| FUTURE DIRECTIONS AND SUMMARY | 327 | ||
| REFERENCES | 327 | ||
| PET-Based Percutaneous Needle Biopsy | 333 | ||
| Key points | 333 | ||
| INTRODUCTION | 333 | ||
| ANATOMIC IMAGING-BASED PERCUTANEOUS NEEDLE BIOPSY | 333 | ||
| FLUORODEOXYGLUCOSE-PET AND PERCUTANEOUS NEEDLE BIOPSY | 334 | ||
| INCORPORATING PET DATA FOR BIOPSY AND THE USAGE OF NAVIGATION TOOLS | 336 | ||
| DATA ON PET-GUIDED BIOPSY BY LOCATION | 339 | ||
| Soft Tissue Lesions | 340 | ||
| Bone Lesions | 341 | ||
| Lung Lesions | 341 | ||
| Mediastinal Lesions | 343 | ||
| Breast Lesions | 345 | ||
| Extrathoracic and Miscellaneous Lesions | 345 | ||
| SUMMARY | 346 | ||
| REFERENCES | 346 | ||
| PET-Based Personalized Management of Infectious and Inflammatory Disorders | 351 | ||
| Key points | 351 | ||
| INTRODUCTION | 351 | ||
| DIAGNOSIS | 352 | ||
| Systemic Infections | 352 | ||
| Bone-Related Infections | 353 | ||
| Vascular Infections | 354 | ||
| Inflammatory Disorders | 354 | ||
| POTENTIAL NOVEL APPLICATIONS | 354 | ||
| SUMMARY | 359 | ||
| REFERENCES | 359 |